Enterprise Value
1.982B
Cash
343.9M
Avg Qtr Burn
N/A
Short % of Float
36.03%
Insider Ownership
18.88%
Institutional Own.
90.11%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WAKIX® (pitolisant) Details Narcolepsy (Adult) | Approved Quarterly sales | |
WAKIX® (pitolisant) Details EDS in Idiopathic Hypersomnia
| Phase 3 Data readout | |
WAKIX® (pitolisant) Details Narcolepsy | Phase 3 Update | |
WAKIX® (pitolisant) Details Muscle degeneration, Muscle weakness | Phase 2 Data readout | |
WAKIX® (pitolisant) Details Genetic disorder, Rare genetic disease, Prader-Willi syndrome | Phase 2 Data readout |